DailyIQ
|
Sector:HealthcareAll sectors
Last updated 9 minutes ago

AMGN·Amgen Inc.

$.
-. (-.%)
After Hours
High
$368.06
Open
$363.08
Market Cap
196.12B
52W High
$391.29
Low
$361.14
P. Close
$363.39
P/E
25.14
52W Low
$269.77
Fwd P/E
64.55
DailyIQ Est.
$360.32
Technical Score (1D)
82
BUY
News Sentiment
70
BULLISH
Truist lifted its price target for Amgen to $340 from $327, citing optimism about a Q2 earnings rebound and broader biotech sector momentum. This upgrade signals that analysts expect stronger near‑term revenue and earnings, which could lift investor sentiment in the coming week. Morgan Stanley, however, trimmed its target to $333 while keeping an equal‑weight rating, reflecting a modest reassessment of short‑term prospects that introduces some uncertainty. The mixed analyst outlook underscores the need to monitor the upcoming Q2 earnings release for any guidance revisions that could resolve the target disparity. Meanwhile, Amgen has voluntarily recalled certain lots of Corlanor and Sensipar due to foreign substances and CGMP deviations, raising immediate quality‑control concerns. The recalls could pressure short‑term earnings and erode confidence, so traders should watch for remediation plans and any regulatory follow‑up in the next few days. In contrast, a federal judge recently blocked Colorado’s proposed 70 % price cap on Enbrel, preserving pricing flexibility for the drug and providing a counterbalancing regulatory win. This relief may support Enbrel revenue, but the concurrent recall risk creates a nuanced risk‑reward profile that investors will need to evaluate. Additionally, the FDA has demanded removal of Tavneos from the U.S. market over alleged trial data manipulation, potentially threatening Amgen’s dividend program. The combination of regulatory relief, recall execution risk, and dividend uncertainty makes the next 1–10 trading days a critical window for earnings, quality‑control updates, and any FDA rulings that could shape the company’s valuation.
Earnings Summary
Amgen Inc. (AMGN) is a global biotechnology firm that discovers, develops, manufactures, and delivers human therapeutics across immunology, oncology, cardiovascular, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. In Q4 2025 the company posted revenue of $9.866 billion and EPS of $5.29, both exceeding estimates of $9.661 billion and $4.828 billion respectively, marking a 2.4% revenue rise from Q3 2025 and a 9.4% EPS gain; the firm also beat estimates in Q3 2025 (EPS $5.64 vs $5.015) and Q1 2026 (EPS $5.15 vs $4.767), underscoring a consistent earnings outperformance. Over the last four quarters, revenue has climbed from $8.149 billion in Q4 2024 to $9.866 billion in Q4 2025, a 21.6% YoY increase, while EPS has risen from $5.31 in Q4 2024 to $5.29 in Q4 2025, reflecting stable profitability despite a slight dip in Q1 2026 revenue to $8.618 billion. The company has maintained a pattern of beating EPS estimates in three of the last four quarters, with revenue growth largely driven by its core product pipeline and favorable pricing dynamics. Recent analyst commentary shows a mixed sentiment: Morgan Stanley trimmed its target to $333 from $340, citing modest growth expectations, while Truist Securities lifted its target to $340 from $327, reflecting confidence in the pipeline; a federal judge’s preliminary injunction blocking Colorado’s proposed 70% price cap on Enbrel has preserved pricing power, whereas a recall of certain Corlanor and Sensipar lots has introduced short‑term operational risk. Investors should watch for the upcoming Q2 2026 earnings release to gauge how the recall cost impact and Enbrel pricing relief translate into guidance, and whether any new pipeline milestones or regulatory developments emerge that could shift the company’s growth narrative.

EPS

EstBeatMiss
$4.00$4.57$5.14$5.71$6.28Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.60 - -
Q1'26$4.77$5.15+8.0%
Q4'25$4.83$5.29+9.6%
Q3'25$5.01$5.64+12.5%
Q2'25$5.28$6.02+14.1%
Q1'25$4.26$4.90+15.0%

Revenue

EstBeatMiss
$7.9B$8.4B$9.0B$9.6B$10.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$9.6B - -
Q1'26$8.6B$8.6B+0.5%
Q4'25$9.7B$9.9B+2.1%
Q3'25 - $9.6B -
Q2'25 - $9.2B -
Q1'25 - $8.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AMGN Stock Snapshot

AMGN is currently trading at $361.61, giving Amgen Inc. a market cap of 196.12B and a P/E ratio of 25.1. Today's range spans $361.14–$368.06, with shares opening at $363.08 and moving down $1.78 (0.5%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 70/100.

Over the past year AMGN has traded between $269.77 and $391.29 - the current price is +34.0% off the 52-week low and -7.6% from the high. 43 analysts cover the stock with a Hold consensus and a mean 12-month target of $355.66 (range $215.00–$427.00), implying downside of -1.6%.

AMGN is showing the kind of bullish setup that active managers add to on dips - 82/100 (BUY), bullish sentiment at 70/100, 196.12B market cap in Healthcare, price $361.61 (in the upper portion of its 52-week range). The current P/E ratio stands at 25.1. At this cap tier, the combination of technical confirmation and positive sentiment is what separates speculative bullish positions from high-conviction ones. Annual range: $269.77–$391.29. The setup is in the latter category.

What makes AMGN's BUY setup (82/100) particularly actionable at 196.12B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $361.61 (in the upper portion of its 52-week range in $269.77–$391.29), with sentiment running bullish at 70/100, the setup rewards conviction-sized positioning more than it does speculative small bets.